Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK39004 Inhalation Suspension in COPD – Phase III, Randomized, Double-Blind, Placebo-Controlled Study
CTR20261276Phase 3Active
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing HSK39004 inhalation suspension with Placebo diluent inhalation suspension (2 arms). Primary endpoint: Change in FEV1 AUC0–12h at Week 12. Started Apr 2026; status: active.
02
Drugs
HSK39004
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20261276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261276.